Japanese Journal of Clinical Oncology Advance Access originally published online on July 26, 2006
Japanese Journal of Clinical Oncology 2006 36(9):602-607; doi:10.1093/jjco/hyl068
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2006 Foundation for Promotion of Cancer Research
Epidemiology Note |
Survival of Cancer Patients Diagnosed between 1993 and 1996: a Collaborative Study of Population-Based Cancer Registries in Japan
Department of Cancer Control and Statistics, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
For reprints and all correspondence: Hideaki Tsukuma, Department of Cancer Control and Statistics, Osaka Medical Center for Cancer and Cardiovascular Diseases, 3-3, Nakamichi 1-chome, Higashinari-ku, Osaka 537-8511, Japan. E-mail: tukuma-hi{at}mc.pref.osaka.jp
Received March 9, 2006; accepted May 26, 2006
Background: Survival of cancer patients has been measured only in some limited areas in Japan until recently. The purpose of the present study was to collect data of fairly high quality on the population-based cancer registries and to estimate relative 5-year survival of cancer patients in Japan.
Methods: We requested 11 population-based cancer registries within the research group to submit individual data of the patients diagnosed from 1993 to 1996, together with the prognosis after 5 years, to the collaborative study secretariat. Ten population-based cancer registries (Miyagi, Yamagata, Niigata, Chiba, Kanagawa, Fukui, Aichi, Osaka, Tottori and Nagasaki) then accepted data submission (373 000 data). Among 10 registries, only 7 registries met the required standards for the quality of registration data and prognosis investigation. The relative 5-year survival calculated by pooling 279 000 data from seven registries was taken as the national estimate of that of cancer patients in Japan.
Results: The relative 5-year survival was 53.6% for all cancers (males: 49.2%, females: 59.4%); the survivals of stomach, large bowel, prostate and kidney cancer patients were from 62 to 68%; those of breast, uterus, larynx, skin, testis, bladder and thyroid cancer patients were from 74 to 92%; those of liver, gall bladder and bile duct, pancreas and lung cancer patients ranged from 6 to 23%.
Conclusion: On the basis of the data from seven population-based cancer registries in Japan, we calculated the relative 5-year survival of cancer patients diagnosed from 1993 to 1996 for the first time.
Key Words: survival • cancer • registry
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. Sato, Y. Ito, A. Ioka, M. Tanaka, and H. Tsukuma Gender Differences in Stomach Cancer Survival in Osaka, Japan: Analyses Using Relative Survival Model Jpn. J. Clin. Oncol., October 1, 2009; 39(10): 690 - 694. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Shibata, T. Matsuda, W. Ajiki, and T. Sobue Trend in Incidence of Adenocarcinoma of the Esophagus in Japan, 1993-2001 Jpn. J. Clin. Oncol., July 1, 2008; 38(7): 464 - 468. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Tabata, Y. Ohno, R. Matsui, H. Sugiyama, Y. Ito, H. Tsukuma, and A. Oshima Partial Cancer Prevalence in Japan up to 2020: Estimates Based on Incidence and Survival Data from Population-based Cancer Registries Jpn. J. Clin. Oncol., February 1, 2008; 38(2): 146 - 157. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Yoshino, N. Boku, Y. Onozawa, S. Hironaka, A. Fukutomi, Y. Yamaguchi, N. Hasuike, K. Yamazaki, N. Machida, and H. Ono Efficacy and Safety of an Irinotecan plus Bolus 5-Fluorouracil and L-Leucovorin Regimen for Metastatic Colorectal Cancer in Japanese Patients: Experience in a Single Institution in Japan Jpn. J. Clin. Oncol., September 1, 2007; 37(9): 686 - 691. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Ito, Y. Ohno, B. Rachet, M. P Coleman, H. Tsukuma, and A. Oshima Cancer Survival Trends in Osaka, Japan: the Influence of Age and Stage at Diagnosis Jpn. J. Clin. Oncol., July 16, 2007; (2007) hym047v1. [Abstract] [Full Text] [PDF]
|
|